Friday, 21 Feb 2020

Biologic/Novel Rx

Datesort descending Type Title Save
10 Aug 2016 Social Abbvies IL-6 drug vobarilizumab (+MTX) failed to meet ACR20 primary endpoint against MTX alone (devloped w/ Ablynx) https://t.co/rAV60pQIcu
23 Aug 2016 Social Idiopathic Recurrent Pericarditis follows ~20% acute pericarditis; responds VERY well to IL-1 inhibition (anakinra) https://t.co/T28ggiTGyA
25 Aug 2016 Social Ixekizumab (Taltz), IL-17 inhibitor, better than Placebo, but same as Humira @24wks in treating psoriatic arthritis https://t.co/mVZ0sMSHdX
30 Aug 2016 Social Dr Carol Langford Gr Rounds - ANCA levels do NOT correlate well with disease activity and should not be used to guide therapy
06 Sep 2016 Social 30% of Biologics us is monotherapy. Choy etal reviews comparative success, reasons, pitfalls of biologic monotherapy https://t.co/UAtLKQbxx7
07 Sep 2016 Social Power doppler synovitis correlates better w/ S100 Calprotectin levels(more than ESR CRP) & w/ low TNFi trough levels https://t.co/gemAqdEUTJ
07 Sep 2016 Social EU grants approval for Orencia (abatacept; IV or SC) for MTX naive (early) RA patients with moderate-severe disease https://t.co/gcGbESdxCp
07 Sep 2016 News Is Biologic Safety Different in the Elderly?
14 Sep 2016 Social TNFi induced Psoriasis can be treated w/ TNFi D/C, another TNFi (48-85% recurrence) or Stelara. Good short review https://t.co/PAtJOOfFIV
14 Sep 2016 Social RTX biosimilar CT-P10 comparable to rituximab in efficacy, pharmacodynamics, & immunogenicity/safety. @DrPetryna https://t.co/hNjcxbF9Mu
20 Sep 2016 News After the 1st TNF Inhibitor, a Non-TNF Biologic is Next Best
20 Sep 2016 Social JIA Uveitis refractory to MTX, DMARDs, TNFi, successfully Rx in 10/17 w/ Tocilizumab after 5.7 mos,7 steroid sparing https://t.co/eDoX3w5g7L
23 Sep 2016 News Restricting High Price Drugs - A Dangerous Trend?
26 Sep 2016 News FDA Approves Stelara for Crohn's Colitis
27 Sep 2016 News Ilaris Gets FDA Approval for Rare Febrile Disorders
28 Sep 2016 Social Yale study of Alopecia (areata or universalis) showed 32% of 66pts improved with tofacitinib 5mg bid after 3 months. https://t.co/DBmnWEujiM
29 Sep 2016 Social Humira and Xeljanz have equal outcomes in patient reported outcomes of efficacy in 12 mos ORAL study. https://t.co/RTcTOenN54
02 Oct 2016 Social Prime Therapeutics shows Xeljanz discontinuations at 30% by 6mos & 44% at 1 yr. 10% use it before MTX/other DMARDs https://t.co/iYAzWwsyi2
02 Oct 2016 News BUILD Study - Baricitinib Shows Rapid Efficacy and X-ray Protection
04 Oct 2016 News Pharma Points Blame at PBMs